BMS-214662 HYDROCHLORIDE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H23N5O2S2.ClH
Molecular Weight	526.073
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.O=S(=O)(N1CC2=C(C=CC(=C2)C#N)N(CC3=CN=CN3)C[C@H]1CC4=CC=CC=C4)C5=CC=CS5

InChI

InChIKey=LBPFLNDUCNNGPS-GNAFDRTKSA-N

InChI=1S/C25H23N5O2S2.ClH/c26-13-20-8-9-24-21(11-20)15-30(34(31,32)25-7-4-10-33-25)23(12-19-5-2-1-3-6-19)17-29(24)16-22-14-27-18-28-22;/h1-11,14,18,23H,12,15-17H2,(H,27,28);1H/t23-;/m1./s1

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C25H23N5O2S2
Molecular Weight	489.612
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12789624 | https://adisinsight.springer.com/drugs/800013625

Bristol-Myers Squibb developed BMS-214662 as potent and selective farnesyl transferase inhibitor with potent antitumor activity. BMS-214662 participated in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers. However, further information is not available.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Protein farnesyltransferase 13 Target ID: CHEMBL2094108 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14741286	Inhibitor 8297		0.7 nM [IC50]

PubMed

Title	Date	PubMed
Targeting RAS signalling pathways in cancer therapy.	2003 Jan	12509763

Patents

Sample Use Guides

In Vivo Use Guide

Patients were treated every week as tolerated with i.v. paclitaxel (fixed dose, 80 mg/m(2)/wk) administered over 1 h followed by i.v. BMS-214662 (escalating doses, 80-245 mg/m(2)/wk) over 1 h starting 30 min after completion of paclitaxel.

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Sat Dec 16 08:18:27 UTC 2023` Edited by `admin` on `Sat Dec 16 08:18:27 UTC 2023`
Record UNII	2ZRT8VWQ9J
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BMS-214662 HYDROCHLORIDE

Common Name

English

1H-1,4-BENZODIAZEPINE-7-CARBONITRILE, 2,3,4,5-TETRAHYDRO-1-(1H-IMIDAZOL-5-YLMETHYL)-3-(PHENYLMETHYL)-4-(2-THIENYLSULFONYL)-, HYDROCHLORIDE (1:1), (3R)-

Systematic Name

English

Code System Code Type Description

PUBCHEM

44189294

Created by admin on Sat Dec 16 08:18:27 UTC 2023 , Edited by admin on Sat Dec 16 08:18:27 UTC 2023

PRIMARY

FDA UNII

2ZRT8VWQ9J

Created by admin on Sat Dec 16 08:18:27 UTC 2023 , Edited by admin on Sat Dec 16 08:18:27 UTC 2023

PRIMARY

CAS

195981-08-9

Created by admin on Sat Dec 16 08:18:27 UTC 2023 , Edited by admin on Sat Dec 16 08:18:27 UTC 2023

PRIMARY

DRUG BANK

DBSALT002163

Created by admin on Sat Dec 16 08:18:27 UTC 2023 , Edited by admin on Sat Dec 16 08:18:27 UTC 2023

PRIMARY

Related Record Type Details


					L2U9GFD244

BMS-214662

PARENT -> SALT/SOLVATE

Amount:

Related Record Type Details


					L2U9GFD244

BMS-214662

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12789624 | https://adisinsight.springer.com/drugs/800013625

Originator

Approval Year

Targets

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12789624 | https://adisinsight.springer.com/drugs/800013625